199 related articles for article (PubMed ID: 37351513)
1. Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis.
Zhang J; Li W; Gong M; Gu Y; Zhang H; Dong B; Guo Q; Pang X; Xiang Q; He X; Cui Y
Front Pharmacol; 2023; 14():1189389. PubMed ID: 37351513
[No Abstract] [Full Text] [Related]
2. Venous Thromboembolism Risk With JAK Inhibitors: A Meta-Analysis.
Yates M; Mootoo A; Adas M; Bechman K; Rampes S; Patel V; Qureshi S; Cope AP; Norton S; Galloway JB
Arthritis Rheumatol; 2021 May; 73(5):779-788. PubMed ID: 33174384
[TBL] [Abstract][Full Text] [Related]
3. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
[TBL] [Abstract][Full Text] [Related]
4. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials.
Ireland PA; Jansson N; Spencer SKR; Braden J; Sebaratnam D
JAMA Dermatol; 2024 Mar; 160(3):281-289. PubMed ID: 38294793
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis.
Ingrassia JP; Maqsood MH; Gelfand JM; Weber BN; Bangalore S; Lo Sicco KI; Garshick MS
JAMA Dermatol; 2024 Jan; 160(1):28-36. PubMed ID: 37910098
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.
Mori S; Ogata F; Tsunoda R
Clin Rheumatol; 2021 Nov; 40(11):4457-4471. PubMed ID: 34554329
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis.
Lowell JA; Sharma G; Swaminath A; Sultan K
Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38704439
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis.
Wei Q; Wang H; Zhao J; Luo Z; Wang C; Zhu C; Su N; Zhang S
Front Pharmacol; 2023; 14():1237234. PubMed ID: 37614310
[No Abstract] [Full Text] [Related]
9. Cardiovascular and Venous Thromboembolic Risk With Janus Kinase Inhibitors in Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis of Randomized Trials.
Maqsood MH; Weber BN; Haberman RH; Lo Sicco KI; Bangalore S; Garshick MS
ACR Open Rheumatol; 2022 Oct; 4(10):912-922. PubMed ID: 35903881
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Olivera PA; Lasa JS; Bonovas S; Danese S; Peyrin-Biroulet L
Gastroenterology; 2020 May; 158(6):1554-1573.e12. PubMed ID: 31926171
[TBL] [Abstract][Full Text] [Related]
12. Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.
Partalidou S; Patoulias D; Deuteraiou K; Avgerou P; Kitas G; Tzitiridou-Chatzopoulou M; Dimitroulas T
Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):10-19. PubMed ID: 38756933
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis.
Zhang X; Shang L; Fan G; Gu X; Xu J; Wang Y; Huang L; Cao B
Front Med (Lausanne); 2021; 8():800492. PubMed ID: 35155477
[TBL] [Abstract][Full Text] [Related]
14. Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
Desai RJ; Pawar A; Weinblatt ME; Kim SC
Arthritis Rheumatol; 2019 Jun; 71(6):892-900. PubMed ID: 30552833
[TBL] [Abstract][Full Text] [Related]
15. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies.
Yan D; Fan H; Chen M; Xia L; Wang S; Dong W; Wang Q; Niu S; Rao H; Chen L; Nie X; Fang Y
Front Pharmacol; 2022; 13():950450. PubMed ID: 36091777
[No Abstract] [Full Text] [Related]
17. Venous and arterial thromboembolic risk of Janus kinase inhibitors: a systematic review with meta-analysis.
Campanaro F; Zaffaroni A; Cacioppo E; Cappelli A; Bertù L; Donadini MP; Squizzato A; Batticciotto A
Rheumatology (Oxford); 2023 Oct; 62(10):3245-3255. PubMed ID: 37202344
[TBL] [Abstract][Full Text] [Related]
18. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
Kahn SR; Morrison DR; Diendéré G; Piché A; Filion KB; Klil-Drori AJ; Douketis JD; Emed J; Roussin A; Tagalakis V; Morris M; Geerts W
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008201. PubMed ID: 29687454
[TBL] [Abstract][Full Text] [Related]
19. Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis.
Bilal J; Riaz IB; Naqvi SAA; Bhattacharjee S; Obert MR; Sadiq M; Abd El Aziz MA; Nooman Y; Prokop LJ; Ge L; Murad MH; Bryce AH; McBane RD; Kwoh CK
Mayo Clin Proc; 2021 Jul; 96(7):1861-1873. PubMed ID: 33840525
[TBL] [Abstract][Full Text] [Related]
20. Risk of Venous Thromboembolism Associated With Tofacitinib and Baricitinib: A Systematic Review and Indirect Meta-Analysis.
Giménez Poderós T; Gallardo Borge S; Vazquez-Ferreiro P
Pharmacotherapy; 2020 Dec; 40(12):1248-1264. PubMed ID: 33064892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
